Solid Tumor Clinical Trials in New York, New York

33 studies are recruiting for solid tumor in New York, New York right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies, page 2

1. A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors

   The purpose of this study is to find out whether selinexor is an effective treatment for people who have a relapsed/refractory Wilms tumor, rhabdoid tumor, MPNST, BCOR-driven sarcoma, or another solid tumor that makes a higher than normal amount of XPO1 or has genetic changes that increase the acti…

   Stage

   Phase 2

   Ages

   1 and older

   Site

   Memorial Sloan Kettering Cancer Center (All protocol activites), New York, New York

   Locations

   16 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT05985161 on ClinicalTrials.gov

2. Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

   This is a first in human study of TNG456 alone and in combination with abemaciclib in patients with advanced or metastatic solid tumors known to have an MTAP loss. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific solid tum…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NYU Langone Health, New York, New York

   Locations

   15 in total

   Run by

   Tango Therapeutics, Inc.

   See if you can join NCT06810544 on ClinicalTrials.gov

3. A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer

   This is a Phase 1b open-label, multicenter study, evaluating the safety, tolerability, preliminary clinical activity, pharmacokinetics (PK), and pharmacodynamics of azenosertib (ZN-c3) in combination with other drugs.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Site 0173, New York, New York

   Locations

   24 in total

   Run by

   K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc

   See if you can join NCT04516447 on ClinicalTrials.gov

4. A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors

   This is a Phase 1/2, first in human (FIH), open-label, multicenter study of BHV-1510 monotherapy and in Combination with Cemiplimab in participants with previously treated, advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Site-117, New York, New York

   Locations

   17 in total

   Run by

   Biohaven Therapeutics Ltd.

   See if you can join NCT06384807 on ClinicalTrials.gov

5. Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors

   This is an open label, multi-center, multiple dose Phase 1 study to evaluate the safety, tolerability, MTD PK, and PD of TJ033721 (givastomig) in subjects with advanced or metastatic solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NYU Langone, New York, New York

   Locations

   21 in total

   Run by

   I-Mab Biopharma US Limited

   See if you can join NCT04900818 on ClinicalTrials.gov

6. A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors

   This phase 1 study will evaluate the safety, tolerability, pharmacokinetics, and efficacy of CUSP06 in patients with platinum-refractory/resistant ovarian cancer and other advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NYU Cancer Institute Clinical Cancer Center, New York, New York

   Locations

   15 in total

   Run by

   OnCusp Therapeutics, Inc.

   See if you can join NCT06234423 on ClinicalTrials.gov

7. Safety and Preliminary Efficacy of OBT076 in Recurrent/Metastatic CD205+ Solid Tumors

   The purpose of this study is to evaluate OBT076, which is a drug that combines an antibody with an anti-cancer drug. This class of drugs are called Antibody-Drug Conjugates (ADC). Antibodies are normally produced in the human body by the immune system to fight infections but can be designed to targ…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Columbia University Medical Center, New York, New York

   Locations

   27 in total

   Run by

   Oxford BioTherapeutics Ltd

   See if you can join NCT04064359 on ClinicalTrials.gov

8. Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors

   This is a Phase 1/2, multicenter, open-label study to evaluate the safety and efficacy of IMP9064 as monotherapy or in combination with PARP inhibitor Senaparib in patients with advanced solid tumors

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Mount Sinai, New York, New York

   Locations

   8 in total

   Run by

   Impact Therapeutics, Inc.

   See if you can join NCT05269316 on ClinicalTrials.gov